New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

Details for Australian Patent Application No. 2007200958 (hide)

International Classifications

Event Publications

22 March 2007 Complete Application Filed

29 March 2007 Application Open to Public Inspection

Published as AU-B-2007200958

7 October 2010 Application Accepted

Published as AU-B-2007200958

3 February 2011 Standard Patent Sealed

19 January 2012 Extension of Term of Standard Patents

AstraZeneca AB The earliest first regulatory approval date provided by the patentee 21 Jun 2011 For the goods BRILINTA ticagrelor Applications Accepted The following application(s) for Extension of Term have been accepted under Section 74. Notice of opposition under Section 75(1) to the undermentioned application(s) for an extension of term may be filed at the Patent Office within the prescribed time.

2 February 2012 Extension of Term of Standard Patents

AstraZeneca AB The earliest first regulatory approval date provided by the patentee 21 Jun 2011 For the goods BRILINTA ticagrelor Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

19 July 2012 Extension granted

AstraZeneca AB The earliest first regulatory approval date provided by the patentee 21 Jun 2011 For the goods BRILINTA ticagrelor Extension of Term of patent pursuant to Section 77 expires on 31 May 2026

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.